01911nas a2200277   4500000000100000008004100001260001500042653002200057653001900079653003000098653001900128653001300147100002100160700001900181700002100200700002100221700001900242700001800261700002200279245009700301856007200398300001100470490000800481520113000489022001401619       2026                            d  c2026-07-0110acolorectal cancer10aDrug Discovery10aHigh-throughput screening10aRetinoblastoma10aSpheroid1 aIrina L. Sinenko1 aFabien Kuttler1 aKseniya Glinkina1 aGerardo Turcatti1 aAdeline Berger1 aPaul J. Dyson1 aFrancis L. Munier00aSpheroid screening: A simplified model driving targeted drug discovery and clinical advances  uhttps://www.sciencedirect.com/science/article/pii/S0753332226006165  a1195800 v2003 aThe increasing number of cancer cases and the prevalence of failed treatments underscore the need for alternative therapeutics and more predictive screening methods. In this context, the field of 3D cultures (termed spheroid, organoid, or tumoroid models) has seen rapid growth in recent years, leading to a range of more physiologically relevant models compared to standard 2D culture methods. However, many of these models face limitations in scalability due to their complex setup, maintenance requirements, and high costs, which restrict their use in drug discovery. In response, we present a simple but robust spheroid model for two distinct types of solid tumors, colorectal cancer and retinoblastoma, specifically designed for high-throughput drug screening. This model is reproducible and cost-effective, utilizing commercially available components and automation. We applied this model to screen chemotherapeutics and used high-content image-based analysis to identify prospective drug candidates. This spheroid model has the potential to advance drug discovery, particularly in challenging areas of cancer research.  a0753-3322